[A23-127] Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Last updated 01.03.2024
Project no.:
A23-127
Commission:
Commission awarded on 04.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Hint of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-127_en